Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-839 with Panitumumab and Irinotecan in RAS Wildtype Colorectal Cancer
NCT03263429Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Aug 2017
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telaglenastat in colorectal cancer (CRC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Maximum Tolerated Dose up to 12 months, Response Rate up to 12 months and 1 more. Started Aug 2017; status: completed.
02
Drugs
telaglenastat
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03263429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263429.